Anti-InlA single-domain antibodies that inhibit the cell invasion of Listeria monocytogenes
Journal of Biological Chemistry · 2023-10 · 299 (10) · 105254
DOI: 10.1016/j.jbc.2023.105254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2023-10. Verfasst von Taichi Yamazaki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, School of Engineering, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Listeria monocytogenes, Bacterial Proteins, Single-Domain Antibodies, Listeriosis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Takeda Science Foundation, Japan Agency for Medical Research and Development, National Center for Global Health and Medicine.
Abstract (Originalsprache)
Listeriosis, caused by infection with Listeria monocytogenes, is a severe disease with a high mortality rate. The L. monocytogenes virulence factor, internalin family protein InlA, which binds to the host receptor E-cadherin, is necessary to invade host cells. Here, we isolated two single-domain antibodies (VHHs) that bind to InlA with picomolar affinities from an alpaca immune library using the phage display method. These InlA-specific VHHs inhibited the binding of InlA to the extracellular domains of E-cadherin in vitro as shown by biophysical interaction analysis. Furthermore, we determined that the VHHs inhibited the invasion of L. monocytogenes into host cells in culture. High-resolution X-ray structure analyses of the complexes of VHHs with InlA revealed that the VHHs bind to the same binding site as E-cadherin against InlA. We conclude that these VHHs have the potential for use as drugs to treat listeriosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, School of Engineering, The University of Tokyo, Tokyo, Japan.
- Medical Device Development and Regulation Research Center, School of Engineering, The University of Tokyo, Tokyo, Japan. Electronic address: s-nagatoishi@g.ecc.u-tokyo.ac.jp.
- Department of Chemistry and Biotechnology, School of Engineering, The University of Tokyo, Tokyo, Japan.
- Department of Microbiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Laboratory of Global Healthcare, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Bioengineering, School of Engineering, The University of Tokyo, Tokyo, Japan; Medical Device Development and Regulation Research Center, School of Engineering, The University of Tokyo, Tokyo, Japan; Depart…
Förderung
- Takeda Science Foundation
- Japan Agency for Medical Research and Development
- National Center for Global Health and Medicine
- Senri Life Science Foundation
- University of Tokyo
- Daiichi Sankyo Foundation of Life Science
- Oita University
- Chemo-Sero-Therapeutic Research Institute
Zitieren
APA
Yamazaki, T., Nagatoishi, S., Yamawaki, T., Nozawa, T., Matsunaga, R., Nakakido, M., Caaveiro, J. M. M., Nakagawa, I., & Tsumoto, K. (2023). Anti-InlA single-domain antibodies that inhibit the cell invasion of Listeria monocytogenes. Journal of Biological Chemistry, 299(10), 105254. https://doi.org/10.1016/j.jbc.2023.105254
Vancouver
Yamazaki T, Nagatoishi S, Yamawaki T, Nozawa T, Matsunaga R, Nakakido M, et al. Anti-InlA single-domain antibodies that inhibit the cell invasion of Listeria monocytogenes. Journal of Biological Chemistry. 2023;299(10):105254. doi:10.1016/j.jbc.2023.105254
BibTeX
@article{Yamazaki2023,
author = {Yamazaki, Taichi and Nagatoishi, Satoru and Yamawaki, Tsukushi and Nozawa, Takashi and Matsunaga, Ryo and Nakakido, Makoto and Caaveiro, Jose M M and Nakagawa, Ichiro and Tsumoto, Kouhei},
title = {Anti-InlA single-domain antibodies that inhibit the cell invasion of Listeria monocytogenes},
journal = {Journal of Biological Chemistry},
year = {2023},
volume = {299},
number = {10},
pages = {105254},
doi = {10.1016/j.jbc.2023.105254}
}
EUVIMED